CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM099465
Első szerző:Jóna Ádám (orvos)
Cím:Pulmonary Toxicity of Hodgkin Lymphoma Treatment : a Prospective Single-Center Study / Jona Adam, Miltenyi Zsofia, Pinczes Laszlo, Kerek Patricia, Bittner Nora, Szilasi Maria, Barna Sandor, Illes Arpad
Dátum:2021
ISSN:1927-1212 1927-1220
Megjegyzések:Background: Standard bleomycin-containing first-line therapy and/or irradiation may cause pulmonary toxicity in Hodgkin lymphoma (HL) patients. Our aim was to prospectively assess effects of chest irradiation, bleomycin administration, and other factors on lung function in the treatment of patients with HL.Methods: Pulmonary function of newly diagnosed HL patients was assessed via a St. George Respiratory Questionnaire, dynamic inhalation lung scintigraphy, spirometry, and an assessment of the diffusion capacity of the lung for carbon monoxide (DLCO) before, during, and after treatment.Results: This prospective study was conducted at the University of Debrecen. The study included 84 patients with classical HL. Most patients received standard doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy. Both intramuscular and intravenous administrations of bleomycin were used. Brentuximab vedotin combination chemotherapy was administered to 12 patients. Mediastinal involved-field irradiation therapy (IFRT) was used to treat 16 patients. Lung scintigraphy revealed pulmonary toxicity more sensitively than DLCO. Intravenous bleomycin administration decreased diethylenetriamine pentaacetic acid clearance. Intramuscular bleomycin had the lowest level of pulmonary toxicity among considered treatments. Currently used, mediastinal IFRT had a lower level of pulmonary toxicity than bleomycin. The current prospec-tive evaluation confirmed previous results that determined that cumulative bleomycin dose and administration are major risk factors for pulmonary toxicity, while the currently used treatment method, mediastinal irradiation, was determined to be relatively safe for treating for HL patients.Conclusion: We agree with decreasing bleomycin dosage and number of cycles administered and we do not recommend avoiding mediastinal IFRT, unless multiple pulmonary risk factors are present.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Hodgkin lymphoma
Pulmonary toxicity
Bleomycin
Irradiation
Brentuximab vedotin
Scintigraphy
Pulmonary fibrosis
Combination therapy
Megjelenés:Journal of Hematology. - 10 : 6 (2021), p. 266-273. -
További szerzők:Miltényi Zsófia (1975-) (belgyógyász, haematológus) Pinczés László Imre (1990-) (általános orvos) Kerek Patrícia (1996-) (Orvos) Bittner Nóra (1963-) (orvos) Szilasi Mária (1953-) (tüdőgyógyász, klinikai immunológus, allergológus, belgyógyász) Barna Sándor (1982-) (kutató orvos) Illés Árpád (1959-) (belgyógyász, haematológus, onkológus)
Pályázati támogatás:UNKP-20-4
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM111963
035-os BibID:(cikkazonosító)100580 (Scopus)85165521769
Első szerző:Lázár József
Cím:Large-scale plasma proteome epitome profiling is an efficient tool for the discovery of cancer biomarkers / Lazar Jozsef, Antal-Szalmas Peter, Kurucz Istvan, Ferenczi Annamaria, Jozsi Mihaly, Tornyi Ilona, Muller Monika, Fekete Janos Tibor, Lamont John, FitzGerald Peter, Gall-Debreceni Anna, Kadas Janos, Vida Andras, Tardieu Nadege, Kieffer Yann, Jullien Anne, Guergova-Kuras Mariana, Hempel William, Kovacs Andras, Kardos Tamas, Bittner Nora, Csanky Eszter, Szilasi Maria, Losonczy Gyorgy, Szondy Klara, Galffy Gabriella, Csada Edit, Szalontai Klara, Somfay Attila, Malka David, Cottu Paul, Bogos Krisztina, Takacs Laszlo
Dátum:2023
ISSN:1535-9476
Megjegyzések:Current proteomic technologies focus on the quantification of protein levels, while little effort is dedicated to the development of systems approaches to simultaneously monitor proteome variability and abundance. Protein variants may display different immunogenic epitopes detectable by monoclonal antibodies. Epitope variability results from alternative splicing, posttranslational modifications, processing, degradation, and complex formation and possess dynamically changing availability of interacting surface structures frequently serve as reachable epitopes, and often carry different functions. Thus, it is highly likely, that the presence of some of the accessible epitopes correlate with function under physiological and pathological conditions. To enable the exploration of the impact of protein variation on the immunogenic epitome first; here, we present a robust and analytically validated protein epitome profiling (PEP) technology for characterizing immunogenic epitopes of the plasma. To this end we prepared mAb libraries directed against the normalized human plasma proteome as a complex natural immunogen. Resulting hybridoma supernatants were selected for mAb production and the corresponding hybridomas were cloned. Monoclonal antibodies react with single epitopes, thus profiling with the libraries is expected to profile many epitopes which we define by the mimotopes, as we present here. Screening blood plasma samples from control subjects (n = 558) and cancer patients (n = 598) for merely 69 native epitopes displayed by 20 abundant plasma proteins resulted in distinct cancer-specific epitope panels that showed high accuracy (AUC 0.826?0.966) and specificity for lung, breast, and colon cancer. Deeper profiling (?290 epitopes of approximately 100 proteins) showed unexpected granularity of the epitope-level expression data and detected neutral and lung-cancer associated epitopes of individual proteins. Biomarker epitope panels selected from a pool of 21 epitopes of 12 proteins were validated in independent clinical cohorts. The results demonstrate the value of PEP as a rich and thus far unexplored source of protein biomarkers with diagnostic potential.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Molecular & Cellular Proteomics. - 22 : 7 (2023), p. 1-18. -
További szerzők:Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Kurucz István Ferenczi Annamária (1986-) (molekuláris biológus, mikrobiológus) Józsi Mihály Tornyi Ilona (1982-) (molekuláris biológus) Müller Mónika Fekete János Tibor Lamont, John FitzGerald, Peter Gall-Debreceni Anna Kádas János (1976-) (molekuláris biológus, biokémikus, kertészmérnök) Vida András (1979-) (molekuláris biológus, genetikus) Tardieu, Nadège Kieffer, Yann Jullien, Anne Guergova-Kuras, Mariana Hempel, William Kovács András László (1969-) (biológus, biológia-kémia tanár) Kardos Tamás (1980-) (pulmonológus, klinikai onkológus) Bittner Nóra (1963-) (orvos) Csánky Eszter (1959-) (tüdőgyógyász, klinikai immunológus, allergológus) Szilasi Mária (1953-) (tüdőgyógyász, klinikai immunológus, allergológus, belgyógyász) Losonczy György Szondy Klára Gálffy Gabriella Csada Edit Szalontai Klára Somfay Attila Malka, David Cottu, Paul Bogos Krisztina Takács László (1955-) (orvos)
Pályázati támogatás:TECH-09-A1-2009-0113; mAbCHIC
Egyéb
GOP-1.2.1-09-2010-0019
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1